23andMe (NASDAQ:ME) Earns “Sell (E+)” Rating from Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of 23andMe (NASDAQ:ME) in a research report released on Saturday,Weiss Ratings reports.

23andMe Stock Performance

ME opened at $3.61 on Friday. The firm’s 50 day simple moving average is $3.49 and its two-hundred day simple moving average is $5.60. The company has a market capitalization of $94.29 million, a PE ratio of -0.14 and a beta of 1.14. 23andMe has a 1-year low of $2.65 and a 1-year high of $16.52.

23andMe (NASDAQ:ME) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($2.32) EPS for the quarter. The company had revenue of $44.07 million during the quarter, compared to analysts’ expectations of $50.30 million. 23andMe had a negative return on equity of 129.98% and a negative net margin of 318.39%.

Hedge Funds Weigh In On 23andMe

Several large investors have recently added to or reduced their stakes in ME. FNY Investment Advisers LLC bought a new stake in shares of 23andMe during the 4th quarter valued at $26,000. MassMutual Private Wealth & Trust FSB purchased a new stake in 23andMe in the 4th quarter worth $40,000. Geode Capital Management LLC raised its holdings in 23andMe by 0.7% during the third quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock valued at $1,476,000 after acquiring an additional 28,252 shares during the period. Vanguard Personalized Indexing Management LLC lifted its position in shares of 23andMe by 410.4% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 88,555 shares of the company’s stock valued at $35,000 after acquiring an additional 71,204 shares in the last quarter. Finally, Point72 DIFC Ltd purchased a new stake in shares of 23andMe during the second quarter worth about $43,000. Hedge funds and other institutional investors own 36.10% of the company’s stock.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.